Preclinical Pharmacology
WuXi Biology offers in integrated services with in vitro biology, DMPK and toxicology studies to provide datasets and evidence for IND-enabling.
Large and expanding infrastructure
- AAALAC-accredited animal facility
- IVC-cage capacity in SPF barrier
Growing number of available animal models
- 1700+ tumor models: 1400+ PDX / 300+ CDX / 80+ syngeneic models
- Gene KO/KI animals
Exploration in new technologies including patient-derived organoids, single cell RNAseq, and NanoString
We offer Pharmacokinetic studies and ADME (stabilities, plasma protein binding, transporter, tissue distribution, metabolic ID, excretion), safety and efficacy studies with both in vitro and in vivo models.
Safety
- In vitro assays
- Protein/enzyme activity, induction & inhibition
- Transferase assays
- Cellular toxicity with primary cell cultures
- ADC off-target screening
- Genetic toxicity
- In vivo toxicity
- Toxicokinetics (TK)
- Systemic & specific tox
- Short & long term tox
- Clinical relevance (dose, dose escalation)
- Clinical safety
Efficacy
- Benchmark, selection
- Animal efficacy test
- Animal models of clinical relevance
- Target engagement
- PD profiling
- Biomarkers
- PK/PD study / PK parameters for efficacy
- Mechanistic pharmacology
- Gene expression profiling (NanoString)
- ‘Omics’ studies
- Disease mechanism
Diseases Areas

Cardiovascular & Metabolic Diseases
Heart failure & stroke | Hypertension | AF | Obesity & diabetes | NASH |Kidney failure | Hyperuricemia
Infectious Diseases
A comprehensive virology platform to support lead ID/Op, SAR, PCC | HDI | AAV/HBV | HBV | RSV | Influenza

Liver, Lung, Kidney, GI Diseases
Lung Fibrosis | ALI | Nephropathy | Acute kidney injuries | kidney fibrosis | Gastric ulcer | IBS